<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04098562</url>
  </required_header>
  <id_info>
    <org_study_id>19-09-1128</org_study_id>
    <nct_id>NCT04098562</nct_id>
  </id_info>
  <brief_title>Efficacy of LL-37 Cream on Bacteria Colonization, Inflammation Response and Healing Rate of Diabetic Foot Ulcers</brief_title>
  <official_title>The Efficacy of LL-37 Cream on Aerobic Bacteria Colonization Pattern, Inflammation Response: Interleukin 1α (IL-1α) and Tumor Necrosis Factor α (TNF-α), and Healing Rate of Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fakultas Kedokteran Universitas Indonesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fakultas Kedokteran Universitas Indonesia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic foot ulcer (DFU) is a common complication of diabetes with global prevalence of
      6.3%. Treatment of diabetic foot ulcer (DFU) is challenging with disappointing outcome. Wound
      debridement, infection control, pressure relief and revascularization are main pillars of DFU
      management. Various substances and modalities are being investigated for their potential
      effects in treating DFU, one of which is LL-37.

      In this randomized, controlled trial, 40 patients with uncomplicated DFU will be enrolled.
      Patients are randomly assigned to undergo twice a week treatment with 0.5 mg/mL LL-37 cream
      (treatment group) or placebo cream (control group) for 4 weeks in addition to standard wound
      care. The primary outcomes are the healing rate measured by wound area and granulation index
      and changes in patterns of aerobic bacteria colonization during the 4-week study duration and
      changes in concentrations of IL-α and TNF-α from fluid collected from DFU on the end of the
      second and third week of study compared to baseline.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of Healing Rate at 1 Week</measure>
    <time_frame>Changes from baseline of granulation index at 1 week</time_frame>
    <description>Measured by difference of granulation index by ImageJ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of Healing Rate at 2 Week</measure>
    <time_frame>Changes from baseline of granulation index at 2 weeks</time_frame>
    <description>Measured by difference of granulation index by ImageJ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of Healing Rate at 3 Week</measure>
    <time_frame>Changes from baseline of granulation index at 3 weeks</time_frame>
    <description>Measured by difference of granulation index by ImageJ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of Healing Rate at 4 Week</measure>
    <time_frame>Changes from baseline of granulation index at 4 weeks</time_frame>
    <description>Measured by difference of granulation index by ImageJ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of Aerobic Bacteria Count and Type of Bacteria Species at 1 Week</measure>
    <time_frame>Changes from baseline of the species of bacteria grown on culture and the quantities of their colonies in CFU/swab at 1 week</time_frame>
    <description>Measured by the species of bacteria grown on culture and the quantities of their colonies in CFU/swab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of Aerobic Bacteria Count and Type of Bacteria Species at 2 Week</measure>
    <time_frame>Changes from baseline of the species of bacteria grown on culture and the quantities of their colonies in CFU/swab at 2 week</time_frame>
    <description>Measured by the species of bacteria grown on culture and the quantities of their colonies in CFU/swab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of Aerobic Bacteria Count and Type of Bacteria Species at 3 Week</measure>
    <time_frame>Changes from baseline of the species of bacteria grown on culture and the quantities of their colonies in CFU/swab at 3 week</time_frame>
    <description>Measured by the species of bacteria grown on culture and the quantities of their colonies in CFU/swab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of Aerobic Bacteria Count and Type of Bacteria Species at 4 Week</measure>
    <time_frame>Changes from baseline of the species of bacteria grown on culture and the quantities of their colonies in CFU/swab at 4 week</time_frame>
    <description>Measured by the species of bacteria grown on culture and the quantities of their colonies in CFU/swab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of Inflammation Marker at 2 Week</measure>
    <time_frame>Changes from baseline at the end of second week</time_frame>
    <description>Measured by the concentrations of IL-α and TNF-α by ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of Inflammation Marker at 3 Week</measure>
    <time_frame>Changes from baseline at the end of third week</time_frame>
    <description>Measured by the concentrations of IL-α and TNF-α by ELISA</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg/mL LL-37 cream, administered twice a week for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cream, administered twice a week for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LL37</intervention_name>
    <description>cream</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard Wound Care</intervention_name>
    <description>Standard wound debridement</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with DFU

          -  Ankle brachial index (ABI) 0.9 - 1.3

          -  Wound area 5 - 20 cm^2

          -  Wound depth until subcutaneous tissue

          -  Without systemic infection, osteomyelitis, septic arthritis, or fasciitis

          -  Subjects are willing to participate by signing consent

        Exclusion Criteria:

          -  Gangrene

          -  On treatment with systemic corticosteroids within 7 days before the start of study

          -  On treatment with systemic antibiotics within 2 days before the start of study

          -  Patients with end stage renal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eliza Miranda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fakultas Kedokteran Universitas Indonesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eliza Miranda, MD</last_name>
    <phone>+628119001018</phone>
    <email>elisamiranda74@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>RS Pusat Angkatan Darat Gatot Soebroto</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>DKI Jakarta</state>
        <zip>10410</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <contact>
      <last_name>Eliza Miranda, MD</last_name>
      <phone>+628119001018</phone>
      <email>elisamiranda74@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Eliza Miranda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luddwi A Rizky, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RSUPN dr. Cipto Mangunkusumo</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>DKI Jakarta</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <contact>
      <last_name>Eliza Miranda, MD</last_name>
      <phone>+628119001018</phone>
      <email>elisamiranda74@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Eliza Miranda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luddwi A Rizky, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RS Persahabatan</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <zip>13230</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <contact>
      <last_name>Eliza Miranda, MD</last_name>
      <phone>+628119001018</phone>
      <email>elisamiranda74@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Eliza Miranda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luddwi A Rizky, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>September 22, 2019</last_update_submitted>
  <last_update_submitted_qc>September 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fakultas Kedokteran Universitas Indonesia</investigator_affiliation>
    <investigator_full_name>Eliza Miranda, MD</investigator_full_name>
    <investigator_title>Staff of Tropical Infection Division, Department of Dermatology and Venereology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

